focus -WSS

focus

author：Wikipedia 2025-09-29 21:27:05 - browse：38

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Timeline: Key moments in fight for gay rights

explore

WSS

Novo: Oral version of Ozempic leads to 15% weight loss

Living organ donors deserve priority status for transplants

Life sciences deals on track to hit lowest point since 2017

Senate panel passes drug pricing bills, but drops one PBM reform

Bispecific antibodies are next new thing in cancer immunotherapy

Readout LOUD podcast: Merger Mondays, Ozempic panic

Wikipedia

focus

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Humana CEO Bruce Broussard to step down in 2024

Supreme Court strikes down use of affirmative action

European regulators recommend Amylyx's ALS drug be rejected

DIEP, the 'gold standard' of breast reconstruction, is under threat

There’s no way to know how good AI health technologies are

Activists slam private health insurers over coverage restrictions

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

There’s no way to know how good AI health technologies are

leisure time

Millions may soon lose Medicaid when they don't have to

Eight reasons why you should get an updated Covid vaccine

A revolution in caring for preterm infants

Xenotransplantation trials will require adjusting expectations, experts say

Nick Jonas talks about managing diabetes along with his career

Patients, doctors are clashing about side effects of hormonal birth control

knowledge

Wikipedia

explore

knowledge